Relapsing features of bile salt export pump deficiency after liver transplantation in two patients with progressive familial intrahepatic cholestasis type 2-Reference-Cited by-同舟云学术

Relapsing features of bile salt export pump deficiency after liver transplantation in two patients with progressive familial intrahepatic cholestasis type 2

Published:2010-11 Issue:5 Volume:53 Page:981-986
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Maggiore Giuseppe,Gonzales Emmanuel,Sciveres Marco,Redon Marie-José,Grosse Brigitte,Stieger Bruno,Davit-Spraul Anne,Fabre Monique,Jacquemin Emmanuel

Publisher

Elsevier BV

Subject

Hepatology

Reference18 articles.

1. Progressive familial intrahepatic cholestasis;Davit Spraul;Orphanet J Rare Dis,2009

2. Davit-Spraul A, Fabre M, Branchereau S, Baussan C, Gonzales E, Stieger B et al. ATP8B1 and ABCB11 analysis in 62 children with normal GGT PFIC: phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology 2010 Jan 28. [Epub ahead of print].

3. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families;Strautnieks;Gastroenterology,2008

4. Hepatocanalicular bile salt excretory pump deficiency in patients with progressive familial intrahepatic cholestasis;Jansen;Gastroenterology,1999

5. Safety of living-related liver transplantation for progressive familial intrahepatic cholestasis;Cutillo;Pediatr Transplant,2006

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EASL Clinical Practice Guidelines on genetic cholestatic liver diseases;Journal of Hepatology;2024-08

2. Clinical symptoms, biochemistry, and liver histology during the native liver period of progressive familial intrahepatic cholestasis type 2;Orphanet Journal of Rare Diseases;2024-02-10

3. Transplantation Pathology;MacSween's Pathology of the Liver;2024

4. Developmental and Inherited Liver Disease;MacSween's Pathology of the Liver;2024

5. Outcomes of 38 patients with PFIC3: Impact of genotype and of response to ursodeoxycholic acid therapy;JHEP Reports;2023-10